PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity. In recent years, several novel therapies with alternative MOAs, such as the IL-12/23 inhibitor ustekinumab, the oral PDE4 inhibitor apremilast, and the IL-17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who have an inadequate response to TNF inhibitors.

Three biologics and three oral agents are in late-phase development for PsA and are expected to launch during the 2018-2028 study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies. In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF inhibitor class.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Key Findings
    • Key Updates
      • November 2019
      • September 2019
      • June 2019
      • November 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for PsA?
        • What Factors Are Constraining the Market for PsA?
      • Drug-Class-Specific Trends
        • TNF Inhibitors
        • IL-12/23 Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • Selective Costimulation Modulators
        • PDE4 Inhibitors
        • JAK Inhibitors
        • cDMARDs
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
        • Pathogenesis
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
        • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Psoriatic Arthritis
        • Diagnosed Prevalent Cases of Psoriatic Arthritis
        • Diagnosed Drug-Treated Prevalent Cases of Psoriatic Arthritis
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • TNF Inhibitors
        • IL-12/23 Inhibitors
        • PDE4 Inhibitors
        • IL-17 Inhibitors
        • JAK Inhibitors
        • Selective Costimulation Modulators
        • cDMARDs
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in PsA
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for PsA
        • IL-17 Inhibitors
        • JAK Inhibitors
        • IL-23 Inhibitors
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • PsA Bibliography

Author(s): Kristine Mackin, PhD; T.J. Arndt, MPH, CPH

Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

joined Decision Resources Group in 2018 as an entry-level epidemiologist and previously worked in basic sciences research academia. earned his Masters in Public Health from the University of Florida, where he conducted an internship focused on developing a clinical model to non-invasively screen for Non-Alcoholic Steatohepatitis (NASH). He also holds a in Microbiology & Cell Science and a in Spanish, both from the University of Florida. During his undergraduate and graduate career, he worked in two physiology-based research labs at the University of Florida, focusing on maternal and fetal stresses during pregnancy and parturition.


Related Reports

Psoriatic Arthritis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Market Outlook: Psoriatic arthritis (PsA) treatment typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics or targeted...

View Details

Psoriatic Arthritis | Unmet Need | Detailed, Expanded Analysis (US & EU)

MARKET OUTLOOK Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (

View Details

Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 3 (US)

Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted ther...

View Details

Psoriatic Arthritis | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of psoriatic arthritis comprises epidemiological estimates of key patient populations across 45 countries worldwide....

View Details